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A B S T R A C T
Isolated methylmalonic aciduria (MMAuria) is primarily caused by deﬁciency of methylmalonyl-CoA mutase
(MMUT or MUT). Biochemically, MUT deﬁciency results in the accumulation of methylmalonic acid (MMA),
propionyl-carnitine (C3) and other metabolites. Patients often exhibit lethargy, failure to thrive and metabolic
decompensation leading to coma or even death, with kidney and neurological impairment frequently identiﬁed
in the long-term. Here, we report a hemizygous mouse model which combines a knock-in (ki) missense allele of
Mut with a knock-out (ko) allele (Mut-ko/ki mice) that was fed a 51%-protein diet from day 12 of life, con-
stituting a bespoke model of MMAuria. Under this diet, mutant mice developed a pronounced metabolic phe-
notype characterized by drastically increased blood levels of MMA and C3 compared to their littermate controls
(Mut-ki/wt). With this bespoke mouse model, we performed a standardized phenotypic screen to assess the
whole-body impairments associated with this strong metabolic condition. We found that Mut-ko/ki mice show
common clinical manifestations of MMAuria, including pronounced failure to thrive, indications of mild neu-
rological and kidney dysfunction, and degenerative morphological changes in the liver, along with less well
described symptoms such as cardiovascular and hematological abnormalities. The analyses also reveal so far
unknown disease characteristics, including low bone mineral density, anxiety-related behaviour and ovarian
atrophy. This ﬁrst phenotypic screening of a MMAuria mouse model conﬁrms its relevance to human disease,
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reveals new alterations associated with MUT deﬁciency, and suggests a series of quantiﬁable readouts that can
be used to evaluate potential treatment strategies.
1. Introduction
Methylmalonic aciduria (MMAuria) is a rare autosomal recessive
inborn error of metabolism caused by deﬁciency of the mitochondrial
enzyme methylmalonyl-CoA mutase (MMUT or MUT) (OMIM entry
*609058) [1]. The MUT enzyme catalyses the reversible isomerization
of L-methylmalonyl-CoA into succinyl-CoA, an intermediate in the tri-
carboxylic acid cycle, by using vitamin B12 (cobalamin, Cbl) in its co-
factor form 5′-deoxyadenosylcobalamin (AdoCbl). In humans, this re-
action represents an important step in propionate catabolism, funneling
metabolites from the breakdown of branched-chain amino acids (va-
line, isoleucine, methionine, and threonine), odd-chain fatty acids, and
the side chain of cholesterol into the tricarboxylic acid cycle [2]. De-
ﬁcient activity of MUT results either from defects of the MUT apo-en-
zyme or from defects of intracellular synthesis of AdoCbl. Apo-enzyme
defects are traditionally divided into mut0 and mut− classes on the basis
of residual in vitro MUT activity, whereby patients classiﬁed as mut−
retain some residual activity and are responsive in vitro to Cbl supple-
mentation while mut0 are not [3,4]. This often translates into mut−
patients presenting later with milder disease than mut0 [4,5]. Bio-
chemically, MMAuria is characterized by the accumulation of meta-
bolites, such as methylmalonic acid (MMA), propionylcarnitine (C3),
and 2-methylcitrate in tissues and body ﬂuids [5]. MMAuria patients
often present in the newborn period with failure to thrive, lethargy,
repeated vomiting and life-threatening metabolic decompensations.
Most surviving patients develop chronic kidney damage, and many
suﬀer from neurological deterioration. As a consequence, the risk of
severe disability or death is very high [6]. Patients are often supple-
mented with carnitine and Cbl, and in order to reduce the throughput of
the MUT pathway, a dietary restriction involving a low-protein intake is
usually implemented [5,7,8].
To study the pathomechanisms of mut-type MMAuria, mouse models
of disease have been utilized. Previously, two Mut knock-out (Mut-ko)
mouse models have been generated, resulting in complete null mutants;
however, most homozygous pups did not survive past 24 h [9,10]. To
circumvent this lethality, in separate studies, adeno-associated virus
delivery [11] and transgene expression [12] in the liver were in-
troduced. A novel hemizygous mouse model of MMAuria was generated
by Forny et al. [13], combining a knock-in (ki) allele with a ko allele
(Mut-ko/ki), whereby the ki allele was based on the p.Met700Lys pa-
tient missense mutation (p.Met698Lys in mouse) [14]. Compared to
their heterozygous littermate controls (Mut-ki/wt), Mut-ko/ki females
showed increased blood and tissue levels of MMA and of C3 normalized
to acetylcarnitine (C2), as well as failure to thrive and renal dysfunc-
tion. However, consistent with the mut− phenotype found in human
patients carrying the p.Met700Lys mutation, this model recapitulated a
milder version of the disease and a dietary strategy was applied to
exacerbate the phenotype. Thereby, Mut-ko/ki mice were fed either a
high-protein or precursor-enriched diet to increase the throughput of
the MUT pathway. These interventions led to more overt signs of the
disease, among which were very high levels of accumulating relevant
metabolites in blood and tissues [13]. Nevertheless, the dietary-driven
increase of the biochemical phenotype could only be shown acutely, as
the mice lost weight too rapidly to continue beyond a few days.
To thoroughly investigate in vivo alterations associated with the
metabolic impairment in MMAuria, one strategy is to perform a sys-
temic phenotyping study that assesses all clinically relevant organ
systems. The full screening approach based on standard protocols may
uncover potential mutation-related abnormalities in the whole body in
a reliable and reproducible manner, without introducing a researcher's
bias as to which systems are expected to be aﬀected [15]. To our
knowledge, no mouse model of MMAuria has yet undergone such an
unbiased phenotyping screen.
We have developed a new strategy of dietary challenge by feeding
our mice with a 51%-protein diet from day 12 of life. In this way, Mut-
ko/ki mice start accumulating metabolites at a very early age, akin to
what is found clinically, but avoid rapid weight loss, enabling long-term
investigation. Using this model, we have performed a broad pheno-
typing screen and found dysfunctions across many organ systems, many
of which parallel clinical ﬁndings in patients with MMAuria. We have
further identiﬁed new phenotypic traits that may form the basis of fu-
ture clinical and molecular investigations.
2. Material and methods
2.1. Ethics statement
In Zurich, all animal experiments were approved by the legal au-
thorities (license 048/2016; Kantonales Veterinäramt Zürich,
Switzerland) and performed according to the legal and ethical re-
quirements. In Munich, mice were maintained according to the German
Mouse Clinic (GMC) housing conditions and German laws. All tests
performed at the GMC were approved by the responsible authority of
the district government of Upper Bavaria, Germany.
2.2. Animal housing
In Zurich, mice were bred and housed in single-ventilated cages
with a 12:12 h light/dark cycle and an artiﬁcial light of approximately
40 Lux in the cage. The animals were kept under controlled humidity
(45–55%) and temperature (21 ± 1 °C) and housed in a barrier-pro-
tected speciﬁc pathogen-free unit. Mice had ad libitum access to ster-
ilized drinking water and to pelleted and extruded mouse diet. All
parameters were monitored continuously. To generate the experimental
Mut-ko/ki and the control Mut-ki/wt mice, Mut-ko/wt females were
crossed with Mut-ki/ki males. In Munich, animal housing was per-
formed in strict accordance with directive 2010/63/EU. Mice were
housed in individually ventilated caging (IVC) systems operating with
positive pressure (Sealsafe plus, GM 500, Tecniplast, Buggugiate, Italy)
under speciﬁc pathogen-free conditions. All mice received autoclaved
wood chips (Lignocel select ﬁne, J. Rettenmaier & Soehne GmbH,
Rosenberg, Germany) and paper stripes (Arbocel crinclets natural
Rettenmaier & Soehne GmbH) as bedding and nesting material, irra-
diated protein rich diet (51%) for rodents (optimized prior to this study,
for details see below) and sterile-ﬁltered tap water ad libitum. Light was
adjusted to a 12:12 h light/dark cycle with a 10 min period of dimmed
light to simulate sunrise/sunset.
2.3. Diet studies
For the optimization of the dietary conditions, mice were fed with
several types of high-protein diets (51%, 42% and 33% of protein) and
a reference diet (18% of protein, diet U8978 version 22). All the diets
were manufactured by Safe and the composition of the high-protein
diets was based on the reference diet. Mouse monitoring entailed reg-
ular weight measurements and blood collections from tail vein.
2.4. Metabolite measurements
Thirty microlitres of blood was collected from tail vein and put on a
M. Lucienne, et al. BBA - Molecular Basis of Disease xxx (xxxx) xxxx
2
ﬁlter card. Whole blood concentration of MMA, acetylcarnitine and
propionylcarnitine was determined on dried blood spots, as previously
described [13]. Measurements were performed in duplicates and
averages were calculated prior to data analysis.
Plasma was prepared by collecting ~50 μL of blood from tail vein in
a tube coated with K2-EDTA before centrifugation at 1500g for 10 min.
Determination of MMA concentration: Plasma and urine samples
(~20 μL and ~70 μL respectively) were analyzed by liquid chromato-
graphy mass spectrometry (LC-MS/MS) on a Thermo Scientiﬁc UltiMate
3000 Rapid Separation LC coupled to an AB Sciex 5500 TripleQuad
mass spectrometer using a commercial kit (Recipe ClinMass® ad-
vanced). Plasma and urine samples were ﬁrst diluted with water (factor
2 and 20 for control plasma and urine respectively, and factor 500 and
50′000 for mutant plasma and urine respectively), to which internal
standard (d3-MMA) was added. The samples were vortexed, cen-
trifuged, the supernatant transferred to HPLC vials, and 2 μL were in-
jected into the instrument. Creatinine was determined by enzymatic
assay on a routine analyzer Alinity c from Abbott Laboratories.
2.5. Blood gases measurements
Blood was collected from tail vein and analyzed immediately for
determination of pH, pCO2 and HCO3− on a Radiometer ABL 800 blood
gas analyzer.
2.6. B12 treatment
Mice were administrated 50 μg/g hydroxocobalamin daily over
50 days, starting at 2 months of age, given intraperitoneally. After one
week of treatment, mice were switched to a 51%-protein diet.
2.7. Phenotypic screening
At the GMC, 30 mutant mice (15 females and 15 males) and 26
controls (14 females and 12 males) were subjected to an extensive
phenotypic screening, including standardized phenotyping in the areas
of dysmorphology, behaviour, neurology, nociception, energy meta-
bolism, clinical chemistry, cardiovascular features, eye, immunology,
and pathology [16] (see also www.mouseclinic.de). The phenotypic
tests were part of the GMC screen and were performed according to
standardized protocols as described [17–19]. The test pipeline started
at the age of 10 weeks. Dependent of the test performed, animal number
may vary, and is indicated in the ﬁgure/table.
2.8. Statistical analysis
In Zurich, the data analysis was performed using Graph Pad (version
8.0.0) and automated R-scripts (version 3.5.1). In Munich, unless
otherwise indicated, the data generated by the GMC was analyzed using
R (version 3.2.3). Tests for genotype eﬀects were made by using t-test,
Wilcoxon rank sum tests, linear models, or ANOVA and posthoc tests, or
Fisher's exact test depending on the assumed distribution of the para-
meter and the questions addressed to the data. A p-value<0.05 has
been used as level of signiﬁcance; a correction for multiple testing has
not been performed (about 500 parameters belonging to 14 diﬀerent
disease areas are measured during the primary screening).
3. Results
3.1. Optimization of dietary challenge
We previously showed that a switch to a high-protein diet (60%-
protein) at approximately day 60 of life triggers a signiﬁcant increase in
metabolite levels in Mut-ko/ki mice [13]. Unfortunately, this is ac-
companied by drastic weight loss requiring the mice to be sacriﬁced
after 4 days. Based on these data, we attempted a new strategy of
dietary challenge. We fed 6-week-old Mut-ko/ki females with a protein-
content diet of 51%, 42% and 33%-protein chow that were isocaloric to
each other and with a reference chow (16%-protein). As might be ex-
pected, a protein-content dependent eﬀect was observed in detection of
Fig. 1. Mut-ko/ki mice exhibit drastically elevated metabolite levels and failure to thrive under a 51%-protein diet. Panels (A)–(B): Impact of high-protein diet
initiated in older (~6-week-old) Mut-ko/ki females. Percentages given represent protein composition in diet (Ref: reference chow, 16%-protein). Measurement of (A)
detectable methylmalonic acid (MMA) in arbitrary units (A.U.) and (B) propionylcarnitine (C3) normalized to acetylcarnitine (C2) in dried blood spots. (C) Change in
body weight after switching to a high-protein diet, with body weight on the day the high-protein diet was introduced taken as 100%. For A–C: Each tracked point
represents a single mouse. The diet shown was provided immediately after the ﬁrst data point. Panels D–F: Impact of 51% protein diet given in younger (12-day-old)
females. (D). Evidence of growth delay in a 19-week-old femaleMut-ko/ki mouse compared to herMut-ki/wt (littermate) sister. Measurement of (E) MMA and (F) C3
normalized to C2 in dried blood spots over the ﬁrst 6 months of life. Each tracked point represents a single mouse. LOD: limit of detection.
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MMA (Fig. 1A) and C3 normalized to C2 (Fig. 1B) detected in dried
blood spots, whereby the 51%-protein diet led to the strongest increase
in biochemical parameters. However,Mut-ko/ki mice challenged with a
51%-protein diet unfortunately also displayed drastic weight loss
(Fig. 1C). We hypothesized that this was due to a sudden reduction in
food intake, linked to the switch to a diﬀerent type of food and pellet
texture (unpublished observations and [20]). To circumvent this
dietary change, we supplied mice with the 51%-protein pellets starting
from day 12 of life, ensuring that from weaning it was the only solid
food available. By this method, although Mut-ko/ki mice were smaller
than their littermates (Fig. 1D), we no longer detected sudden weight
loss (Fig. S1), enabling long-term studies. An initial cohort of female
mice on this diet, observed for almost six months, retained persistently
elevated metabolite levels (Fig. 1E and F), suggesting this was a suitable
strategy.
3.2. A biochemically relevant bespoke mouse model
Using the Mut-ko/ki mice (or Mut-ki/wt littermate controls) on a
51% protein diet from day 12 of life, our bespoke model, we in-
vestigated larger cohorts of mice including both sexes. The massive
elevations in metabolic parameters presented in Fig. 1 were conﬁrmed
in cohorts of up to 15 mice per genotype per sex for both MMA (Fig. 2A)
and C3/C2 (Fig. 2B) at both 5 and 20 weeks of age. On average, Mut-
ko/ki males and females showed an ~100-fold increase in MMA levels
and ~4-fold increase in C3/C2 compared to their littermates and both
parameters were stable over time (Fig. 2A and B). This corresponds to
an approximate 15-fold increase in MMA and 3-fold increase in C3/C2
compared toMut-ko/ki mice on a reference diet (compare Fig. 1A and B
with Fig. 2A and B). The physiological relevance of these elevations
were conﬁrmed in a cohort of female mice wherebyMut-ko/ki mice had
plasma MMA ranging from 100 to 1000 μM, while urinary MMA was in
the range of 10–100 mol/mol creatinine, concentrations which are
~100-fold higher than their littermate controls (Fig. 2C and D). Since
some mut− patients are treated with intramuscular injection of Cbl, we
further performed daily intraperitoneal hydroxocobalamin injections in
Mut-ko/ki females raised on normal chow and switched to a 51%-
protein diet seven days after the start of injections. These mice showed
a reduction in MMA levels compared to sham treated mice (injected
with NaCl) over seven weeks of time (Fig. S2), indicating they were
partially amenable to Cbl treatment.
In order to determine which further clinically translatable disease
aspects are present in these mice, we performed a full standardized
phenotyping of our bespoke MMAuria mouse model, completed as part
of the mandate of the German Mouse Clinic (GMC) to characterize
mouse models of human disease [15,16,21]; https://www.mouseclinic.
de). In accordance with our optimized protocol, for further studies Mut-
ko/ki and Mut-ki/wt mice were challenged with a 51%-protein diet
from day 12 of life. Cohorts of 15 mice per sex/genotype were used for
in-depth phenotyping. Although 60 mice were generated, 4 were ex-
cluded from the ﬁnal analysis - 1 Mut-ki/wt female died after the ﬁrst
test, and 3 Mut-ki/wt males had very low body mass combined with
extremely high liver enzyme activities, suggesting that they suﬀered
from chronic liver disease, which was conﬁrmed upon autopsy.
3.3. Conﬁrmation that Mut-ko/ki mice show failure to thrive
The ﬁrst and most obvious phenotypic ﬁnding in theMut-ko/ki mice
was that of growth delay in both males and females (Fig. 3A and B),
consistent with observations in our initial cohort (Figs. 1D and S1).Mut-
ko/ki mice of both sexes were considerably lighter than their hetero-
zygous littermate controls at time of ﬁrst weighing (approx. day 24 of
life), a diﬀerence that was further exaggerated over the following
4 weeks (Fig. 3A and B). After approximately day 70 of life Mut-ko/ki
mice showed similar growth curves to their littermates. Nevertheless,
they remained underweight. To identify whether their reduced growth
was associated with decreased food and water intake, these parameters
were measured over a period of 21 h, starting 5 h before lights-oﬀ in the
evening. Over this time, Mut-ko/ki mice ate and drank less than their
littermates (Fig. 3C and D). When adjusted for the body weight dif-
ference, food and water consumption did not diﬀer between genotypes.
Fig. 2. Impact of 51% protein diet initiated at a younger age (12-day-old) in large cohorts of both sexes. Measurement of methylmalonic acid (MMA) in dried blood
spots in (A) 5-week-old and 20-week-old mice. Measurement of propionylcarnitine (C3) normalized to acetylcarnitine (C2) in dried blood in (B) 5-week-old and 20-
week-old mice. p < 0.0001. Signiﬁcant diﬀerence determined by Wilcoxon Mann Whitney Tests using automated R-scripts (version 3.5.1). C-D: MMA con-
centrations in plasma (C) and urine (D) in 5 Mut-ki/wt and 5 Mut-ko/ki female mice. Urine MMA was normalized to simultaneous urine creatinine from each sample
(closed circles) or average creatinine from all samples (open circles).
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3.4. Along with smaller size, Mut-ko/ki mice show bone alterations
Consistent with reduced weight, we found in our initial cohort that
Mut-ko/ki females appeared smaller than their littermates (Fig. 1D). In
this larger cohort, we found that their decreased stature corresponded
to decreased tibia length (females 17.69 [16.8, 17.72] mm inMut-ko/ki
versus 18.42 [18.14, 18.64] mm in Mut-ki/wt, p-value<0.05; males
(17.94 [17.89, 18.02] mm inMut-ko/ki versus 18.36 [18.29, 18.71] mm
in Mut-ki/wt, p-value<0.05; median [ﬁrst quartile, third quartile], p-
values by Wilcoxon rank-sum test:). Using dual-energy X-ray absorp-
tiometry (DEXA) analysis of both the whole skeleton (excluding the
head) and lumbar spine, we found bone area and bone mineral content
(BMC) to be decreased when males and females were combined
(Table 1) or evaluated separately (Tables S1 and S2). As the magnitude
of BMC reduction was greater than the decrease in bone area, decreased
bone mineral density (BMD) was identiﬁed in these mice (Table 1).
Therefore, Mut-ko/ki mice have shorter and less dense bones than their
littermates. These changes were not due to chronic exposure to meta-
bolic acidosis, since blood pH, pCO2 and bicarbonate were not found to
be changed in selected female mice under the same dietary conditions
(Fig. S3). We further found that Mut-ko/ki males and females had re-
duced grip strength using only two paws or with all four paws. How-
ever, regression analysis indicated that this strongly corresponded to
their decreased body weight (Fig. S4). Therefore, muscle function does
not appear to be primarily aﬀected by the defect.
3.5. Mut-ko/ki mice display hypoactivity and anxiety-related behaviour
We further performed an examination of behavioural and neurolo-
gical related changes. Using an open ﬁeld test, Mut-ko/ki males and
females had decreased exploratory behaviour, as they spent less time
(Figs. 4A and S5A) and had reduced distance (Figs. 4B and S5B) in the
Fig. 3. Impact of optimized dietary strategy on growth, food intake and water consumption. Evidence of growth delay in Mut-ko/ki females (A) and Mut-ko/ki males
(B) compared toMut-ki/wt littermate controls of each sex over 4 months of life (n≥ 12 for each). Growth of wild-type C57BL/6J mice fed with a normal diet (19.3%
protein) is shown as mean (black line) ± 1 S.D. (grey shading) for each sex (data from The Jackson Laboratory, https://www.jax.org/jax-mice-and-services/strain-
data-sheet-pages/body-weight-chart-000664). Monitoring of food intake (C) and water consumption (D) over 21 h at the age of 14 weeks. Each point represents a
single mouse.
Table 1
DEXA analysis of whole mouse and region-speciﬁc bone mineral density and content.
Mut-ki/wt (n = 26) Mut-ko/ki (n = 30) Δ% ((Mut-ko/ki - Mut-ki/wt)/Mut-ki/wt) ANOVA
genotype
p-value
Total weight whole mouse DEXA [g] 24.0 ± 3.7 18.8 ± 2.5 −21.7 < 0.001
Bone area whole mouse [cm2] 8.67 ± 0.62 7.45 ± 0.45 −14.1 < 0.001
BMC whole mouse [mg] 554.820 ± 76.149 412.151 ± 48.226 −25.7 < 0.001
BMD whole mouse [mg/cm2] 63.7 ± 4.1 55.1 ± 3.5 −13.5 < 0.001
Bone area ROI [cm2] 0.47 ± 0.03 0.41 ± 0.03 −12.8 < 0.001
BMC ROI [mg] 33.823 ± 4.304 24.038 ± 3.519 −28.9 < 0.001
BMD ROI [mg/cm2] 72.5 ± 6.4 58.2 ± 5.1 −19.7 < 0.001
For each genotype male and female mice were pooled. Data provided as group means± standard deviation and ANOVA (Tukey multiple comparisons of means).
BMC: bone mineral content; BMD: bone mineral density; ROI: region of interest.
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centre of the arena, consistent with anxiety-related behaviour. The open
ﬁeld test also revealed a clear decrease in locomotor and exploratory
activities, as indexed by a diminution in the total distance travelled
(Figs. 4C and S5C) and total rearing activities (Figs. 4D and S5D), which
was corroborated using a modiﬁed SHIRPA protocol (Fig. 4E). This
hypoactivity was accompanied by a reduced locomotor speed in the
open ﬁeld (Table S3) and a shorter latency to fall in the rotarod test,
this latter indicating a potential decrease in motor coordination and
balance (Fig. 4F). In contrast to these acute tests in a novel environ-
ment, when measured over 21 h in an environment close to home cage
conditions, we did not observe any diﬀerence in average distance or
rearing betweenMut-ko/ki andMut-ki/wt mice (Table S4), although we
note the variability between mice in these longer-term tests. In sum,
these ﬁndings support a hypothesis thatMut-ko/ki mice are anxious and
hypoactive, at least when exposed to novel environments.
3.6. Decreased thermal sensitivity
We evaluated the thermal sensitivity of Mut-ko/ki and Mut-ki/wt
mice using a hotplate assay. We found that both the ﬁrst (Fig. 5A) and
second (Fig. 5B) reactions of the Mut-ko/ki mice were retarded com-
pared to their littermates. However, the types of reactions (ﬁrst hind
paw shaking, then licking) were not diﬀerent (data not shown). These
retarded hotplate reactions may indicate hypoalgesia.
3.7. Further neurological ﬁndings
Further neurology and behaviour tests did not identify any major
diﬀerences between Mut-ko/ki and Mut-ki/wt mice. Apart from de-
creased locomotor activity, all observation parameters, part of the
SHIRPA protocol, including tremor, transfer arousal, gait, etc. were not
signiﬁcantly diﬀerent between the two groups (Table S5). We also did
not identify speciﬁc deﬁciencies of vision, with the caveat that axial
Fig. 4. Mut-ko/ki mice are hypoactive and show anxiety-related behaviour compared to Mut-ki/wt. In an open ﬁeld test used as a novel environment (20 min test
duration), evidence of decreased percent permanence time spent in the center, p-value 0.009 (A) and percent distance spent in the center, p-value 0.004 (B),
decreased distance travelled, p-value<0.001 (C), and decreased number of rears, p-value< 0.001 (D). During the SHIRPA test (30 s), evidence of reduced loco-
motor activity, p-value<0.001 (E). The rotarod revealed slightly reduced latencies to fall in Mut-ko/ki males and females, p-value 0.034 (F).
Fig. 5. Mut-ko/ki mice show a decreased thermal sensitivity. First (A) and second (B) reactions to the hotplate (p-value< 0.001 and p-value 0.002 respectively).
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length and lens thickness were slightly decreased in some Mut-ko/ki
mice (Fig. S6 and Table S6). Finally, we did not ﬁnd speciﬁc hearing
deﬁciencies as determined by acoustic startle (Table S7) and auditory
brain response (Fig. S7) tests.
3.8. Evidence of early mild kidney dysfunction
In previous studies, electrolytes were found to be altered in Mut-ko/
ki mice, suggestive of kidney dysfunction [13]. Here we found in-
creased plasma levels of sodium, chloride and inorganic phosphate
along with decreased total protein and alpha-amylase levels in Mut-ko/
ki mice of either sex, while urea levels were increased in females only
(Table 2). Nevertheless, our bespoke mouse model did not show any
changes in plasma levels of calcium, potassium, creatinine, albumin and
lactate dehydrogenase (Table 2). Standard hematoxylin and eosin
staining in 20-week-old mice did not reveal any histological alterations
in the kidney (Fig. S8).
3.9. Mut-ko/ki mice show signs of decreased cardiac function and
hematological alterations
Awake electrocardiography and echocardiography recordings were
performed in Mut-ko/ki and Mut-ki/wt mice to investigate the heart.
Echocardiography identiﬁed a decrease in cardiac output (Fig. 6A),
with no morphological or functional alterations noted (Tables S8 and
S9). However, electrocardiography revealed a decreased heart rate and
a concurrently increased RR length (Fig. 6B and Table S9). Further-
more, QT duration (Fig. 6C) and QT corrected for heart rate (QTc,
Fig. 6D) were increased in the mutant male cohort. Both QT and QTc
were also initially identiﬁed to be increased in the female mutant co-
hort, however, following removal of a single outlier, they were found to
be unchanged (Fig. 6C and D). Histological investigation by hematox-
ylin and eosin staining did not identify any changes (Fig. S9).
Hematological investigations further indicated mild macrocytic
anemia, as red blood cell counts, hemoglobin and hematocrit were all
slightly decreased while mean cell volume and cellular hemoglobin
content were increased in mutant mice (Table 3). These ﬁndings were
associated with a decrease in plasma iron (Fig. 7A), as well as calcu-
lated total iron binding capacity (Fig. 7B) and transferrin saturation
(Fig. 7C) in Mut-ko/ki mice. Further, there was evidence of thrombo-
cytopenia as platelet counts and plateletcrit were decreased. Although
platelet distribution width and mean platelet volume were not sig-
niﬁcantly altered, the proportion of large platelets (PLCR) was slightly
reduced, predominantly in females (Table 3).
Total white blood cell counts, in contrast, were increased inMut-ko/
ki compared to controls (Table 3), which is in contradiction to what is
observed in patients [5]. Increased white blood cell counts are con-
sistent with the slightly elevated tumor necrosis factor alpha levels
found in plasma (Fig. S10A). However, individual leukocyte popula-
tions were similar between Mut-ko/ki and Mut-ki/wt mice, whereby
Mut-ko/ki females had slightly decreased granulocyte and decreased
natural killer but increased natural killer T cell populations (Table S10).
Likewise, plasma interleukin 6 (Fig. S10B) was not changed in the
mutant mice and immunoglobulins, were within the normal range, al-
though the concentration of IgA in Mut-ko/ki mice was marginally
higher than in Mut-ki/wt mice (Table S11).
3.10. Alterations in the ovaries of Mut-ko/ki females
Histological investigations in ovaries of Mut-ko/ki females at the
age of 20 weeks revealed an ovarian atrophy consisting of pre-
dominance of cords of pale stained hyperplastic interstitial tissue with
fewer follicles with 100% penetrance (5 out of 5) compared to the
control group (0 out of 5) (Fig. 8A and B). Histology of the testes,
epididymis, funiculus spermaticus, prostrate, male accessory glands,
uterus and vagina did not reveal any signiﬁcant diﬀerence between
Mut-ko/ki and their heterozygous littermate controls (data not shown).
3.11. Alterations in the liver of Mut-ko/ki mice
Mutant mice had a hepatocellular hypertrophy compared to control
mice (Fig. 9). The hepatocellular hypertrophy comprised of enlarged
hepatocytes tinctorially distinct and granular cytoplasm. High variation
in the size of the cell nucleus (anisonucleosis) was also present as well
as a high number of binucleated forms and a high rate of intranuclear
inclusions in the liver of Mut-ko/ki mutant mice compared to controls.
4. Discussion
4.1. Establishment of a clinically relevant MMAuria mouse model
In this study, we established an optimized dietary strategy to chal-
lenge our MMAuria mouse model with a 51%-protein diet from day 12
of life. Compared to their littermates or the same mice on reference
chow, this bespoke mouse model displays a pronounced metabolic
phenotype characterized by elevated metabolite levels in blood, similar
to patient levels. Correspondingly, according to published algorithms
used for newborn screening, Mut-ko/ki and Mut-ki/wt mice would be
correctly diagnosed as disease positive and negative respectively [22].
We also found that MMA concentrations in Mut-ko/ki mice challenged
with a high-protein diet were responsive to Cbl treatment, suggesting
that these mice are an excellent model to test novel treatments against
Table 2
Alterations of Mut-ko/ki plasma clinical chemistry measures.
Females Males p-Value
Mut-ki/wt
(n = 14)
Mut-ko/ki
(n = 15)
Mut-ki/wt
(n = 12)
Mut-ko/ki
(n = 15)
Sex Genotype Sex:genotype
Sodium [mmol/l] 153 ± 2 156 ± 4 153 ± 2a 156 ± 4 0.924 0.005 0.986
Potassium [mmol/l] 4.4 ± 0.6 4.3 ± 0.7 3.8 ± 0.3a 4.2 ± 0.5 0.028 0.366 0.15
Chloride [mmol/l] 113.1 ± 2.1 115.2 ± 2.7 113.4 ± 2.2a 114.4 ± 2.9 0.744 0.028 0.431
Total protein [g/l] 47.7 ± 1.6 44 ± 2.2 47.9 ± 1.5 45.5 ± 1.9 0.087 <0.001 0.173
Albumin [g/l] 24.3 ± 1.4 23.2 ± 1.1 23.6 ± 1.2 23.9 ± 1.1 0.967 0.187 0.04
Creatinine enz. [μmol/l] 12.83 ± 2.69 13.2 ± 3.54 12.06 ± 1.48 11.24 ± 2.99 0.079 0.766 0.437
Urea [mmol/l] 17.91 ± 2.36 22.85 ± 1.34 22.09 ± 2.48 22 ± 1.88 0.003 <0.001 <0.001
alpha-Amylase [U/l] 518.06 ± 42.53 424.62 ± 49.28 662.57 ± 55.66 506.68 ± 43.67 < 0.001 <0.001 0.018
LDH [U/l] 169.2 ± 47.9 167.3 ± 37 142.7 ± 59.8 190.1 ± 105.8 0.921 0.222 0.187
Calcium [mmol/l] 2.21 ± 0.08 2.21 ± 0.08 2.18 ± 0.04 2.22 ± 0.08 0.466 0.344 0.245
Inorganic phosphate [mmol/l] 2.9 ± 0.46 3.57 ± 0.83 3.01 ± 0.3 3.42 ± 0.79 0.907 0.003 0.45
Data provided as mean ± sd. Genotype p-value was calculated by a linear model.
Plasma levels in ad libitum fed Mut-ko/ki and Mut-ki/wt mice. LDH: Lactate Dehydrogenase.
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MMAuria. It also suggests that patients harbouring the missense mu-
tation p.Met700Lys, the equivalent mutation to the mouse p.Met698Lys
in our Mut-ko/ki model, may be responsive to high dose parenteral
vitamin B12 treatment in vivo.
In addition to elevated metabolite levels, we also found signs of
common clinical manifestations of disease. The most prominent one,
growth delay accompanied by decreased feeding and drinking, is akin
to failure to thrive in patients. In MMAuria failure to thrive is one of the
most prominent clinical ﬁndings in the ﬁrst months to years of life and
may be the revealing sign in patients that have not been diagnosed
through a neonatal metabolic crisis or by newborn screening programs.
In our mice, this failure to thrive is possibly related to the hypoactivity
we also identiﬁed and may be due to complex multi-organ metabolic
interactions, which are worth investigating further. We further ob-
served a mild kidney impairment, characterized by small changes in
electrolytes but no histological changes. These ﬁndings may be sug-
gestive of early mild and likely pre-clinical kidney alterations in the
Mut-ko/ki mice, with the potential of progression over time. In patients,
renal complications are common in the course of the disease, with 47%
presenting with chronic kidney disease by 6 years, and 12–14% with
Fig. 6. Mut-ko/ki mice show decreased cardiac function. Echocardiography: evidence of decreased cardiac output, overall p-value both genders 0.01 (A).
Electrocardiography: evidence of decreased heart rate, p-value females 0.001, p-value males< 0.001 (B), increased QT p-value females 0.032, p-value males 0.001
(C) and increased heart-rate corrected QT (QTc) p-value females 0.354, p-value males 0.015 (D).
Table 3
Hematological ﬁndings.
Females Males p-Value
Mut-ki/wt
(n = 14)
Mut-ko/ki
(n = 15)
Mut-ki/wt
(n = 12)
Mut-ko/ki
(n = 15)
Sex Genotype Sex:genotype
RBC [Mio/mm3] 11.57 ± 0.57 10.83 ± 0.64 11.43 ± 0.69 10.89 ± 0.56 0.812 < 0.001 0.531
HGB [g/dl] 18.41 ± 0.96 17.53 ± 0.89 17.82 ± 0.92 17.27 ± 0.96 0.092 0.006 0.502
HCT [%] 56.16 ± 2.53 54.19 ± 3.06 54.44 ± 2.94 53.75 ± 2.07 0.139 0.069 0.374
MCV [ﬂ] 48.5 ± 0.65 50.13 ± 0.74 47.75 ± 0.75 49.47 ± 0.99 0.002 < 0.001 0.847
MCH [pg] 15.91 ± 0.32 16.2 ± 0.35 15.6 ± 0.49 15.87 ± 0.34 0.002 0.008 0.897
MCHC [g/dl] 32.79 ± 0.54 32.37 ± 0.81 32.73 ± 0.52 32.12 ± 0.75 0.414 0.006 0.595
RDW [%] 13.04 ± 0.41 12.99 ± 0.36 13.61 ± 0.59 13.63 ± 0.73 < 0.001 0.916 0.818
WBC [103/mm3] 10.29 ± 2.87 15.58 ± 4.88 11.1 ± 2.33 12.51 ± 3.15 0.234 0.001 0.044
PLT [103/mm3] 910 ± 147 792.93 ± 82.79 1067.58 ± 115.2 882.73 ± 107.92 < 0.001 <0.001 0.277
MPV [ﬂ] 6.28 ± 0.12 6.17 ± 0.13 6.26 ± 0.09 6.28 ± 0.12 0.179 0.193 0.051
PDW [fL] 5.54 ± 0.17 5.45 ± 0.26 5.55 ± 0.07 5.49 ± 0.12 0.612 0.09 0.723
PLCR [%] 2.43 ± 0.55 1.87 ± 0.52 2.33 ± 0.33 2.17 ± 0.4 0.432 0.006 0.11
PCT [%] 0.57 ± 0.09 0.49 ± 0.04 0.67 ± 0.07 0.55 ± 0.07 < 0.001 <0.001 0.414
Values measured in EDTA-blood samples. Data provided as mean ± sd. All p-values calculated by a linear model. RBC: red blood cell count, HGB: hemoglobin, HCT:
hematocrit, MCV: mean corpuscular volume, MCH: mean corpuscular hemoglobin, MCHC: mean corpuscular hemoglobin concentration, RDW: red blood cell dis-
tribution width, WBC: white blood cell, PLT: platelet count, MPV: mean platelet volume, PDW: platelet distribution width, PLCR: platelet large cell ratio, PCT:
plateletcrit.
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end-stage renal disease by adulthood [5]. A similar case is also true for
neurological changes. Our model did not display the common neuro-
logical signs often described in patients, such as movement disorders
and seizures [5]. However, we did identify reduced motor performance,
altered thermal sensitivity and changes in anxiety-related behaviour. As
with the kidney dysfunction, it is possible that these changes represent
mild neurological changes, which either will get worse over time or
illustrate diﬀerences in disease manifestation between mice and hu-
mans. We do note that this is the ﬁrst evidence of neural dysfunction
identiﬁed in a model of MMAuria. Altogether, these data validate the
clinical relevance of our model. Finally, Mut-ko/ki mice exhibited his-
topathological changes in the liver, such as hepatocellular hypertrophy,
granular cytoplasm and formation of body inclusion. This latter might
be secondary to an increase in the amount of cytosolic proteins or in the
number of organelles such as mitochondria, endoplasmic reticulum or
peroxisomes [23]. Liver abnormalities have been reported in MMAuria
patients, such as hepatomegaly, histological abnormalities from ﬁbrosis
to cirrhosis and enlarged mitochondria accompanied with respiratory
chain dysfunction [7,24–27]. More rarely, hepatoblastoma and hepa-
tocellular carcinoma have also been documented in MMAuria [28,29].
Given the dual roles of the liver in metabolite detoxiﬁcation and energy
metabolism, further studies to delineate its role in MMAuria may be
invaluable to understanding disease progression.
By comparison with this model on reference chow [13], our new
high-protein diet studies reveal, as might be expected, that most mea-
sured biochemical and clinical aspects either remain the same or are
worsened in severity for mice on the high-protein diet long-term. Long-
term growth comparison indicates that Mut-ko/ki mice have a much
more pronounced failure to thrive when on a high protein diet, espe-
cially in the ﬁrst 50 days of life, while both studies found elevated MMA
and C3/C2 levels when mice were on a high-protein diet versus a re-
ference diet. However, both with and without a high-protein diet, we
Fig. 7. Mut-ko/ki mice show hematological alterations. Plasma levels of iron, p-value< 0.001 (A), total iron binding capacity, p-value< 0.001 (B) and calculated
transferrin saturation, p-value 0.001 (C) in ad libitum fed Mut-ko/ki and Mut-ki/wt mice. Hematology values measured in EDTA-blood samples.
Fig. 8. Mut-ko/ki mice exhibit alterations in the ovaries. Ovary from a Mut-ki/
wt mouse (A): many corpora lutea ( ), various stages of follicular development
(arrows) and less amounts of interstitial tissue, all compatible with a normally
cycling mouse. Ovary from a Mut-ko/ki mouse (B): predominance of cords of
pale stained hyperplastic interstitial tissue ( ) with fewer follicles. Light mi-
crographs of ovarian tissue stained with hematoxylin and eosin. In the upper
panels, black bar represents 500 μm and in the lower panels, it represents
100 μm. All histological examinations were performed on mice at 20 weeks of
age.
Fig. 9. Histopathological ﬁndings in liver. (A), (C) and (E) are representative
light micrographs of liver sections from a Mut-ki/wt mouse; (B), (D) and (F) are
representative from a Mut-ko−/ki mouse. All histological examinations were
performed on mice at 20 weeks of age. (A) and (B), H&E staining 20× mag-
niﬁcation. (A) Shows the normal appearance of the hepatocytes with clear
cytoplasm containing glycogen. The nucleus is centrally located, round and
contents one or more nucleoli. (B) By comparison, in the liver of a Mut-ko−/ki
mouse, hepatocytes have condensed dark staining and may be enlarged, show
single cell necrosis (marked in circles), high variation in the size of the cell
nucleus (anisonucleosis) (arrows) and mitosis (arrowhead). (C–F) PAS staining.
(D) The liver of mutant mice shows hepatocellular hypertrophy: consisting of
enlarged hepatocytes tinctorially distinct with a diﬀuse distribution pattern,
better seen with lower magniﬁcation (10×). (F) The higher magniﬁcation
(40×) allows visualization of cytoplasm granulation (red arrow) coinciding
with an intranuclear inclusion (black arrow), nucleus degeneration (arrow-
head) and/or unicellular necrosis. (For interpretation of the references to colour
in this ﬁgure legend, the reader is referred to the web version of this article.)
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found only small perturbations of electrolyte levels in plasma, in-
dicative of mild early kidney dysfunction, but no histological changes in
the kidney. This suggests that even on a high-protein diet Mut-ko/ki
mice represents a mild model of kidney disease.
4.2. Phenotyping screen reveals rare and potentially new clinical
manifestations of disease
In addition to conﬁrming at least mild versions of common clinical
disease manifestations, we further identiﬁed less common and novel
disease symptoms in our mice. This includes decreased iron levels, red
blood cells, platelet and plateletcrit, and an increase in mean corpus-
cular volume. MMAuria patients usually have normal hematology va-
lues but neutropenia and pancytopenia were already noted as acute and
chronic presentations of the disease [5]. Leukopenia, thrombocytopenia
and anemia have also been described in patients [5,7,30,31], whereby
anemia has been potentially linked to chronic kidney failure due to an
insuﬃcient erythropoietin production. Our results on one hand reﬂect
the thrombocytopenia described in patients with isolated MMAuria and
on the other indicate impaired erythropoiesis and macrocytic anemia,
which is a typical consequence of complete cobalamin deﬁciency [32]
but not otherwise known in isolated MMAuria.
In addition, Mut-ko/ki animals showed alterations in electro-
cardiography recordings, namely elevated RR and QTc lengths. A pro-
longed QTc interval causes premature action potentials during the late
phases of depolarization and can increase the risk of ventricular ar-
rhythmia or abnormal electrical conduction in the heart. Increased QTc
interval, along with cardiomyopathy, is a common and feared mani-
festation of the related disorder propionic aciduria - a disease due to a
defect of propionyl-CoA carboxylase, two enzymatic steps upstream of
MUT - and has also been described in MMAuria [5]. Since many of the
other disease manifestations are shared between propionic aciduria and
MMAuria, it has been hypothesized that alterations in the heart may be
secondary due to the accumulation of propionic acid and other meta-
bolites, which are known to be drastically elevated in propionic acid-
uria and to a lesser degree in MMAuria. Alternatively, these cardiac
observations could be secondary to impairments in other organ systems.
Further investigation is therefore warranted to conﬁrm the nature of
the cardiac defects in this model. Nevertheless, these data highlight the
utility of this murine model to bridge the gap from bench to bedside.
In terms of novel ﬁndings, we identiﬁed decreased bone mineral
content and density in Mut-ko/ki mice, which could be correlated with
the risk of osteopenia and osteoporosis previously described in
MMAuria patients [5,8]. It is often discussed whether this risk is ia-
trogenic in patients receiving a metabolic diet containing low protein,
calcium and vitamin D levels [5]. Interestingly, our ﬁndings, provided
by mutant and control mice given the same high-protein chow, tend to
refute this hypothesis. To our knowledge, decreased bone density has
not been thoroughly explored in patients so far. However, with the
currently increasing life span patients have experienced over the last
decades, this may become an important secondary eﬀect later in life
and should be monitored. We also found ovarian atrophy, which could
be associated with an ovarian follicular insuﬃciency or impaired reg-
ulation of ovarian folliculogenesis. In mice, ovarian atrophy typically
represents an age-related change (e.g.>1 year old) but when it occurs
prematurely (20 weeks old) it represents an aberrant state [33]. Al-
though MUT is known to be moderately expressed at the mRNA and
protein levels in ovarian tissue in humans (The Human Protein Atlas,
https://www.proteinatlas.org/) and mice [34], this is to our knowledge
the ﬁrst time that ovaries have been investigated in MMAuria. This
suggests that the observed alterations might be caused by an impaired
follicular reserve in Mut-ko/ki females. This may be consistent with the
premature menopause reported in a 36-year-old female patient with
MMAuria and a 45-year-old female patient suﬀering from propionic
aciduria [35,36]. Again, in light of the better clinical management in
current times, having children may be an option for some patients in
the near future. In this case, it will be interesting to identify whether
their ability to do so is aﬀected, and if so, how they can best be sup-
ported.
5. Conclusions
In sum, we optimized a bespoke mouse model of MMAuria, and by
performing a broad phenotypic screen not only identiﬁed common
clinical manifestations of the disease, but also novel presentations. It
will be important to determine whether these latter are truly applicable
to humans or possibly due to the divergence between human and mouse
biology. We suggest attention should be paid to decreased cardiac
function, bone mineral density especially in aging patients, for signs of
liver damage in both sexes and reproductive capacity in females.
So far, the treatments that have been attempted in MMAuria mouse
models were assessed by investigating individual biomarkers only, thus
limiting their clinical assessment. In this study, we identiﬁed quantiﬁ-
able readouts, such as body weight, bone mineral density and content,
hypoactivity in the acute setting, plasma electrolyte levels, QTc, and
number of follicles. Once conﬁrmed and studied in patients, these
readouts would enable a comprehensive clinical output that could be
used to assess the eﬃcacy of potential novel therapeutic avenues, such
as gene or mRNA therapy. Finally, many of the symptoms identiﬁed in
these mice are likely related to metabolic alterations aﬀecting energy. A
more in-depth study of these changes may provide an exciting oppor-
tunity to elucidate further pathophysiological mechanisms of the dis-
ease.
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